Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Wiley 2019-10-01
Loạt:Cancer Medicine
Những chủ đề:
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non‐small cell lung cancer
treatment duration
Truy cập trực tuyến:https://doi.org/10.1002/cam4.2420

Internet

https://doi.org/10.1002/cam4.2420

Những quyển sách tương tự